- Sales of Innovative Products Up by 27.2% Year-on-Year to RMB7.8 Billion
- Profit Attributable to Owners of the Parent from Continuing Operations Surges 140.2%
- Continues R&D Investment Speeds up Globalization to Promote Innovation

- 創新產品收入升至人民幣78億元 同比增長27.2%
- 來自持續經營業務之歸屬於母公司持有者盈利升140.2%
- 持續投入研發 以國際化加速推動創新

- 创新产品收入升至人民币78亿元 同比增长27.2%
- 来自持续经营业务之归属于母公司持有者盈利升140.2%
- 持续投入研发 以国际化加速推动创新

- 創新藥及仿製藥雙豐收 收入達人民幣288.7億元
- 經調整非《香港財務報告準則》歸母淨利潤達人民幣34.6億元

- 创新药及仿制药双丰收 收入达人民币288.7亿元
- 经调整非《香港财务报告准则》归母净利润达人民币34.6亿元

- Dual Success of Innovative Drugs and Generic Drugs
- Revenue Recorded RMB28.87 Billion
- Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Recorded RMB3.46 Billion

- 創新藥及仿製藥雙豐收 收入達人民幣288.7億元
- 經調整非《香港財務報告準則》歸母淨利潤達人民幣34.6億元

- Innovative R&D Yields Fruitful Results Once Again, Revenue Rises to RMB6.13 Billion
- Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent up 14.0%
- New Products Boost Performance Associated Revenue up 39.6%

- 创新研发再结硕果 收入升至61.3亿元
- 经调整非《香港财务报告准则》归母净利润升14.0%
- 新产品助推业绩 相关收入增长39.6%

- 創新研發再結碩果 收入升至61.3億元
- 經調整非《香港財務報告準則》歸母淨利潤升14.0%
- 新產品助推業績 相關收入增長39.6%

創新產品 繼續豐收 收入達人民幣262.0億元
經調整非《香港財務報告準則》歸母淨利潤達人民幣25.9億元

Innovative Products Continued to Deliver and Perform Excellently
Revenue Recorded RMB26.20 Billion
Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Recorded RMB2.59 Billion

创新研发稳步推进 收入升至152.8亿元
经调整非《香港财务报告准则》归母净利润升1.2%
二季度增长强劲复苏 收入狂飙30.0%
经调整非《香港财务报告准则》归母净利润升20.7%

創新研發穩步推進 收入升至152.8億元
經調整非《香港財務報告準則》歸母淨利潤升1.2%
二季度增長強勁復蘇 收入狂飆30.0%
經調整非《香港財務報告準則》歸母淨利潤升20.7%

Steadily Advances Innovation and R&D
Revenue Climbs to RMB15.28 Billion
Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent up 1.2%
Strong Recovery in Q2 Revenue up 30.0%
Adjusted Non-HKFRS Profit Attributable to the Owners of the Parent up 20.7%

收入增长7.1%至人民币287.8亿元
经调整非《香港财务报告准则》归母净利润增长16.4%至人民币29.9亿元
创新药销售收入占比达到23.5%

收入增長7.1%至人民幣287.8億元
經調整非《香港財務報告準則》歸母淨利潤增長16.4%至人民幣29.9億元
創新藥銷售收入佔比達到23.5%

Revenue Up by 7.1% to RMB28.78 Billion
Adjusted non-HKFRS Profit Attributable to the Owners of the Parent Up by 16.4% to RMB2.99 Billion
Sales of Innovative Products Accounts for 23.5% of Revenue

获益于多年高研发投入 新品销售收入占比达43.5%